The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases

Author:

Zhang Shenghong1234ORCID,Zhu Mengqin1234,Zhang Han34,Liu Hanhui1234,Fan Xin34,Zhang Jiajia34,Yu Fei1234ORCID

Affiliation:

1. Shanghai Clinical College, Anhui Medical University, Shanghai 200040, China

2. The Fifth Clinical Medical College, Anhui Medical University, Hefei 230032, China

3. Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200040, China

4. Institute of Nuclear Medicine, Tongji University School of Medicine, Shanghai 200040, China

Abstract

Lung metastasis substantially influences the survival of thyroid cancer (TC) patients. This study sought to investigate factors impacting the survival of differentiated thyroid cancer patients with lung metastases (DTC–LM) undergoing radioiodine therapy (RAI) after thyroid surgery. The retrospective study encompassed 609 TC patients with lung metastases. Survival outcomes—specifically, overall survival (OS) and thyroid cancer-specific survival (TCSS)—were examined through both univariate and multivariate Cox regression analyses. Radioiodine therapy (RAI)’s impact on DTC–LM patient survival was further assessed with the Kaplan–Meier survival curve. Of the 609 TC patients with lung metastases, 434 (71.3%) were found to have undergone thyroid surgery after a median follow-up of 59 months. Anaplastic thyroid cancer (ATC), stage IV, and lung metastases associated with other metastases were identified as risk factors for OS and TCSS in TCLM patients. RAI therapy significantly enhances survival in DTC–LM patients followed by primary site surgery under the age of 55, PTC patients, and those with single organ metastases at lung.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Shanghai Key Laboratory of Molecular Imaging

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3